2024

• Scharl, S., Kroeze, S., Guckenberger, M., Krafcsik, M., Hruby, G., Emmett, L., Schmidt-Hegemann, N., Trapp, C., Spohn, S., Henkenberens, C., et al (2024). European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy. Radiotherapy and Oncology, 194, 110215. [More Information]
• Leow, B., Eade, T., Hruby, G., Lieng, H., Hsiao, E., Brown, C., Kneebone, A. (2024). Prognostic impact of prostate-specific membrane antigen positron emission tomography (PSMA PET) staging for clinically node-positive prostate cancer. Journal of Medical Imaging and Radiation Oncology. [More Information]
• Schuler, T., Carroll, S., Hruby, G., Jayamanne, D., Kneebone, A., Lamoury, G., Morgia, M., Stevens, M., Brown, C., Gallego, B., Booth, J., Eade, T., Kipritidis, J., Back, M., Bergamin, S., et al (2024). Real-World Implementation of Simulation-Free Radiation Therapy (SFRT-1000): A Propensity Score-Matched Analysis of 1000 Consecutive Palliative Courses Delivered in Routine Care. International Journal of Radiation Oncology Biology Physics. [More Information]
• Trapp, C., Grosu, A., Guckenberger, M., Hruby, G., Kirste, S., Koerber, S., Kroeze, S., Peeken, J., Rogowski, P., Scharl, S., et al (2024). Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis. European Journal of Nuclear Medicine and Molecular Imaging. [More Information]

2023

• Wong, J., Allwright, M., Hruby, G., Margaret Roberts, J., Carr, A., Jin, F., Gett, R., Meagher, A., Hillman, R. (2023). Anal cancer: a 20-year retrospective study from Australia. ANZ Journal of Surgery, 93(11), 2697-2705. [More Information]
• Tse, B., Molloy, M., Bergamin, S., Steffen, P., Hruby, G., Pavlakis, N., Clarke, S., Evans, J., Engel, A., Kneebone, A. (2023). CD11c+ and IRF8+ cell densities in rectal cancer biopsies predict outcomes of neoadjuvant chemoradiotherapy. OncoImmunology, 12(1), 2238506. [More Information]
• Cheng, Q., Poynten, I., Jin, F., Grulich, A., Ong, J., Hillman, R., Hruby, G., Howard, K., Newall, A., Boettiger, D. (2023). Cost-effectiveness of screening and treating anal pre-cancerous lesions among gay, bisexual and other men who have sex with men living with HIV. The Lancet Regional Health. Western Pacific, 32. [More Information]
• Zamboglou, C., Peeken, J., Janbain, A., Katsahian, S., Strouthos, I., Ferentinos, K., Farolfi, A., Koerber, S., Debus, J., Vogel, M., Hruby, G., et al (2023). Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer. JAMA Network Open, 6(5), e2314748. [More Information]
• Ahmed, A., Gargett, M., Madden, L., Mylonas, A., Chrystall, D., Brown, R., Briggs, A., Nguyen, T., Keall, P., Kneebone, A., Hruby, G., Booth, J. (2023). Evaluation of deep learning based implanted fiducial markers tracking in pancreatic cancer patients. Biomedical Physics & Engineering Express, 9(3). [More Information]
• Horsley, P., Koo, C., Eade, T., Hsiao, E., Emmett, L., Brown, C., Kneebone, A., Hruby, G. (2023). Mapping of Local Recurrences After Radical Prostatectomy Using 68-Gallium Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: Implications for Postprostatectomy Radiation Therapy Clinical Target Volumes. International Journal of Radiation Oncology Biology Physics, 115(1), 106-117. [More Information]
• Solomonidou, N., Germanou, D., Strouthos, I., Karagiannis, E., Farolfi, A., Koerber, S., Debus, J., Peeken, J., Vogel, M., Vrachimis, A., Kroeze, S., Guckenberger, M., Hruby, G., et al (2023). PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml. European Journal of Nuclear Medicine and Molecular Imaging. [More Information]
• Roberts, M., Gianacas, C., Papa, N., De Abreu Lourenco, R., Dhillon, A., Allen, R., Fontela, A., Kaur, B., Emmett, L., Conduit, C., Hruby, G., et al (2023). The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy. BJU International. [More Information]

2022

• Horsley, P., Kneebone, A., Eade, T., Hruby, G. (2022). Don't throw the baby out with the bath water. The Prostate, 82(3), 397-398. [More Information]
• Eade, T., Kneebone, A., Hruby, G., Booth, J., Hsiao, E., Le, A., Kwong, C., Atyeo, J., Brown, C., Hunter, J., et al (2022). Early Outcomes and Decision Regret Using PSMA/MRI-Guided Focal Boost for Prostate Cancer SBRT. Practical Radiation Oncology, 12(3), e201-e206. [More Information]
• Roberts, M., Chatfield, M., Hruby, G., Nandurkar, R., Roach, P., Watts, J., Cusick, T., Kneebone, A., Eade, T., Ho, B., Stricker, P., et al (2022). Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups. BJU International, 130(S3), 32-39. [More Information]
• Schuler, T., Wong, S., Bergamin, S., Hruby, G., Back, M., Roderick, S., Eade, T. (2022). In Regard to Roos et al. al. "?>. International Journal of Radiation Oncology Biology Physics, 112(1), 260-261. [More Information]
• Zamboglou, C., Strouthos, I., Sahlmann, J., Farolfi, A., Serani, F., Medici, F., Cavallini, L., Morganti, A., Trapp, C., Koerber, S., et al (2022). Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy. International Journal of Radiation Oncology Biology Physics, 113(5), 1015-1024. [More Information]
• Williams, S., Liang, C., Guminski, A., Hruby, G., Chan, D. (2022). Outcome of patient with myasthenia gravis with the use of immunotherapy in metastatic Merkel cell carcinoma. Oxford Medical Case Reports, 2022 (2), 67-70. [More Information]
• Horsley, P., Sheehan-Dare, G., Mastrocostas, K., Fung, C., Kneebone, A., Eade, T., Emmet, L., Lalak, A., Hruby, G. (2022). Prostate adenocarcinoma with mucinous features – is it PSMA avid? Journal of Medical Imaging and Radiation Oncology, 66(5), 637-640. [More Information]
• Jambor, M., Ashrafizadeh, A., Nahm, C., Clarke, S., Pavlakis, N., Kneebone, A., Hruby, G., Gill, A., Mittal, A., Samra, J. (2022). The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on patients’ survival. World Journal of Surgical Oncology, 20(1). [More Information]

2021

• Chou, A., Seyed Ahadi, M., Arena, J., Sioson, L., Sheen, A., Fuchs, T., Pavlakis, N., Clarke, S., Kneebone, A., Hruby, G., et al (2021). A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes with a Proposal for a Novel Approach. American Journal of Surgical Pathology, 45(3), 394-404. [More Information]
• Toby, J., Eade, T., Hruby, G., Kneebone, A., Aherne, N., Brown, C., Guo, L., Hoffmann, M., Shakespeare, T. (2021). Assessing ISUP prostate cancer grade groups in patients treated with definitive dose escalated external beam radiation. Radiotherapy and Oncology, 162, 91-97. [More Information]
• Wong, S., Roderick, S., Kejda, A., Atyeo, J., Grimberg, K., Porter, B., Booth, J., Hruby, G., Eade, T. (2021). Diagnostic Computed Tomography Enabled Planning for Palliative Radiation Therapy: Removing the Need for a Planning Computed Tomography Scan. Practical Radiation Oncology, 11(2), e146-e153. [More Information]
• Oh, B., Boyle, F., Pavlakis, N., Clarke, S., Guminski, A., Eade, T., Lamoury, G., Carroll, S., Morgia, M., Kneebone, A., Hruby, G., Stevens, M., Molloy, M., Back, M., et al (2021). Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review. Frontiers in Oncology, 11, 706331. [More Information]
• Bell, L., Eade, T., Hruby, G., Bromley, R., Kneebone, A. (2021). Intra-fraction displacement of the prostate bed during post-prostatectomy radiotherapy. Radiation Oncology, 16(1), 20-1-20-11. [More Information]
• Schuler, T., Back, M., Hruby, G., Carroll, S., Jayamanne, D., Kneebone, A., Stevens, M., Lamoury, G., Morgia, M., Wong, S., Booth, J., Eade, T., et al (2021). Introducing Computed Tomography Simulation–Free and Electronic Patient-Reported Outcomes–Monitored Palliative Radiation Therapy into Routine Care: Clinical Outcomes and Implementation Experience. Advances in Radiation Oncology, 6(2), 100632. [More Information]
• Schuler, T., Hruby, G., Eade, T. (2021). Patient-reported outcome measures (PROMs) in palliative radiotherapy. Radiotherapy and Oncology, 154, e10-e11. [More Information]
• Parsonson, A., Connolly, E., Lee, M., Hruby, G., Sandroussi, C., Merrett, N., Samra, J., Mittal, A., Tse, R., Grimison, P. (2021). Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study. ANZ Journal of Surgery, 91(11), 2447-2452. [More Information]
• Wijetunga, A., Chua, T., Nahm, C., Pavlakis, N., Clarke, S., Chan, D., Diakos, C., Maloney, S., Ashrafi-Zadeh, A., Kneebone, A., Gill, A., Mittal, A., Samra, J., et al (2021). Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy: Survival in advanced pancreatic cancer. European Journal of Surgical Oncology, 47(10), 2543-2550. [More Information]
• Oh, B., Boyle, F., Pavlakis, N., Clarke, S., Eade, T., Hruby, G., Lamoury, G., Carroll, S., Morgia, M., Kneebone, A., Stevens, M., Molloy, M., Kong, B., Back, M., et al (2021). The gut microbiome and cancer immunotherapy: Can we use the gut microbiome as a predictive biomarker for clinical response in cancer immunotherapy? Cancers, 13(19), 4824. [More Information]
• Oh, B., Eade, T., Lamoury, G., Carroll, S., Morgia, M., Kneebone, A., Hruby, G., Stevens, M., Boyle, F., Clarke, S., Molloy, M., Back, M., et al (2021). The gut microbiome and gastrointestinal toxicities in pelvic radiation therapy: A clinical review. Cancers, 13(10), 2353. [More Information]

2020

• Emmett, L., Tang, R., Nandurkar, R., Hruby, G., Roach, P., Watts, J., Cusick, T., Kneebone, A., Ho, B., Chan, L., Stricker, P., et al (2020). 3-Year Freedom from Progression After 68Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. Journal of Nuclear Medicine, 61(6), 866-872. [More Information]
• Oar, A., Lee, M., Le, H., Hruby, G., Dalfsen, R., Pryor, D., Lee, D., Chu, J., Holloway, L., Briggs, A., Samra, J., Kneebone, A., et al (2020). Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). Practical Radiation Oncology, 10(3), e136-e146. [More Information]
• Emmett, L., Hruby, G. (2020). Clinical impact of PET imaging in prostate cancer management. Current Opinion in Urology, 30(5), 649-653. [More Information]
• Shepherd, M., Bromley, R., Stevens, M., Morgia, M., Kneebone, A., Hruby, G., Atyeo, J., Eade, T. (2020). Developing knowledge-based planning for gynaecological and rectal cancers: a clinical validation of RapidPlan(TM). Journal of Medical Radiation Sciences, 67(3), 217-224. [More Information]
• Itchins, M., Chua, T., Arena, J., Jamieson, N., Nahm, C., O'Connell, R., Bailey, E., Schembri, G., Gill, A., Kneebone, A., Hruby, G., Mittal, A., Pavlakis, N., Clarke, S., Samra, J. (2020). Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. Pancreas, 49(2), 224-229. [More Information]
• Bergamin, S., Eade, T., Kneebone, A., Booth, J., Hsiao, E., Schembri, G., Szymura, K., Le, A., Kwong, C., Brown, C., Hruby, G., et al (2020). Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 108(5), 1172-1178. [More Information]
• Hewson, E., Nguyen, D., O'Brien, R., Poulsen, P., Booth, J., Greer, P., Eade, T., Kneebone, A., Hruby, G., Moodie, T., Keall, P., et al (2020). Is multileaf collimator tracking or gating a better intrafraction motion adaptation strategy? An analysis of the TROG 15.01 stereotactic prostate ablative radiotherapy with KIM (SPARK) trial. Radiotherapy and Oncology, 151, 234-241. [More Information]
• Keall, P., Nguyen, D., O'Brien, R., Hewson, E., Ball, H., Poulsen, P., Booth, J., Greer, P., Hunter, P., Wilton, L., Eade, T., Kneebone, A., Hruby, G., Hardcastle, N., Gebski, V., et al (2020). Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial. International Journal of Radiation Oncology Biology Physics, 107(3), 530-538. [More Information]

2019

• Collier, N., Kneebone, A., Hruby, G., McCloud, P., Booth, J., Eade, T. (2019). A simple algorithm to predict non-compliance with organ at risk dose-volume constraints when planning intensity modulated post-prostatectomy radiation treatment: 'Why we should put the CART before the horse'. Journal of Medical Imaging and Radiation Oncology, 63(4), 546-551. [More Information]
• Hong, A., Fogarty, G., Dolven-Jacobsen, K., Burmeister, B., Lo, S., Haydu, L., Vardy, J., Nowak, A., Dhillon, H., Ahmed, T., Shivalingam, B., Long, G., Menzies, A., Hruby, G., Paton, E., Steel, V., Williams, N., Scolyer, R., Morton, R., Thompson, J., et al (2019). Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology, 37(33), 3132-3141. [More Information]
• Schuler, T., Kipritidis, J., Eade, T., Hruby, G., Kneebone, A., Mario, P., Grimberg, K., Richardson, K., Evill, S., Evans, B., et al (2019). Big Data Readiness in Radiation Oncology: An Efficient Approach for Relabeling Radiation Therapy Structures With Their TG-263 Standard Name in Real-World Data Sets. Advances in Radiation Oncology, 4(1), 191-200. [More Information]
• Bergamin, S., Eade, T., Kneebone, A., Kench, J., Sved, P., Biset, J., Hruby, G. (2019). Ductal Carcinoma of the Prostate: An Uncommon Entity With Atypical Behaviour. Clinical Oncology, 31(2), 108-114. [More Information]
• Bell, L., Eade, T., Hruby, G., Bromley, R., Kneebone, A. (2019). Implementing daily soft tissue image guidance with reduced margins for post-prostatectomy radiotherapy: research-based changes to clinical practice. Journal of Medical Radiation Sciences, 66(4), 259-268. [More Information]
• Hruby, G., Guminski, A., Thompson, J. (2019). Management of Regional Lymph Nodes in Patients with Merkel Cell Carcinoma Following a Positive Sentinel Node Biopsy: Less May be More, But is Either Enough? Annals of Surgical Oncology, 26(2), 315-317. [More Information]
• Lieng, H., Kneebone, A., Hayden, A., Christie, D., Davis, B., Eade, T., Emmett, L., Holt, T., Hruby, G., Pryor, D., et al (2019). Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 140, 68-75. [More Information]
• Eade, T., Hruby, G., Booth, J., Bromley, R., Guo, L., O'Toole, A., Le, A., Wu, K., Rasiah, K., Chalasani, V., Kneebone, A., et al (2019). Results of a Prospective Dose Escalation Study of Linear Accelerator - Based Virtual Brachytherapy (BOOSTER) for Prostate Cancer; Virtual HDR Brachytherapy for Prostate Cancer. Advances in Radiation Oncology, 4(4), 623-630. [More Information]
• Hewson, E., Nguyen, D., O'Brien, R., Kim, J., Montanaro, T., Moodie, T., Greer, P., Hardcastle, M., Eade, T., Kneebone, A., Booth, J., Keall, P., et al (2019). The accuracy and precision of the KIM motion monitoring system used in the multi-institutional TROG 15.01 Stereotactic Prostate Ablative Radiotherapy with KIM (SPARK) trial. Medical Physics, 46(11), 4725-4737. [More Information]
• Van Gysen, K., Stevens, M., Guo, L., Jayamanne, D., Veivers, D., Wignall, A., Pang, L., Guminski, A., Lee, A., Hruby, G., Taylor, A., et al (2019). Validation of the 8th edition UICC/AJCC TNM staging system for HPV associated oropharyngeal cancer patients managed with contemporary chemo-radiotherapy. BMC Cancer, 19(1), 1-8. [More Information]
• Lo, S., Hong, A., Haydu, L., Ahmed, T., Paton, E., Steel, V., Hruby, G., Tran, A., Morton, R., Nowak, A., Vardy, J., Dhillon, H., Scolyer, R., Thompson, J., Fogarty, G., et al (2019). Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan. Trials, 20(1), 1-13. [More Information]

2018

• Hruby, G., Eade, T., Emmett, L., Ho, B., Hsiao, E., Schembri, G., Guo, L., Kwong, C., Hunter, J., Byrne, K., Kneebone, A. (2018). 68Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer. Asia-Pacific Journal of Clinical Oncology, 14(4), 343-346. [More Information]
• Oh, B., Eade, T., Kneebone, A., Hruby, G., Lamoury, G., Pavlakis, N., Clarke, S., Zaslawski, C., Marr, I., Costa, D., Back, M. (2018). Acupuncture in Oncology: The Effectiveness of Acupuncture May Not Depend on Needle Retention Duration. Integrative Cancer Therapies, 17(2), 458-466. [More Information]
• Van Gysen, K., Kneebone, A., Eade, T., Guminski, A., Hruby, G. (2018). Advanced Renal Cell Cancer and Low-Dose Palliative Radiation Treatment: A Case of a Substantial and Sustained Treatment Response. Case Reports in Oncology, 11(3), 756-762. [More Information]
• Kneebone, A., Hruby, G., Harris, G., Rasiah, K., Vass, J., Whalley, D., McCloud, P., Louw, S., Guo, L., Eade, T. (2018). Contemporary salvage post prostatectomy radiotherapy: Early implementation improves biochemical control. Journal of Medical Imaging and Radiation Oncology, 62(2), 240-247. [More Information]
• Byrne, K., Eade, T., Kneebone, A., Guo, L., Hsiao, E., Schembri, G., Kwong, C., Hunter, J., Emmett, L., Hruby, G. (2018). Delineating sites of failure following post-prostatectomy radiation treatment using 68Ga-PSMA-PET. Radiotherapy and Oncology, 126(2), 244-248. [More Information]
• Itchins, M., Arena, J., Pavlakis, N., Nahm, C., Gibbs, E., Mohamudally, A., Maher, R., Bailey, D., Schembri, G., Gill, A., Diakos, C., Khasraw, M., Hruby, G., Kneebone, A., Mittal, A., Samra, J., Clarke, S., et al (2018). Pattern of care and survival of pancreatic ductal adenocarcinoma in a multi-disciplinary high-volume centre. Gastroenterology & Hepatology, 9(5), 185-189. [More Information]
• Poulsen, M., Macfarlane, D., Veness, M., Estall, V., Hruby, G., Kumar, M., Pullar, A., Tripcony, L., Rischin, D. (2018). Prospective analysis of the utility of 18-FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03. Journal of Medical Imaging and Radiation Oncology, 62(3), 412-419. [More Information]
• Lieng, H., Hayden, A., Christie, D., Davis, B., Eade, T., Emmett, L., Holt, T., Hruby, G., Pryor, D., Shakespeare, T., Kneebone, A., et al (2018). Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 129(2), 377-386. [More Information]
• Roach, P., Francis, R., Emmett, L., Hsiao, E., Kneebone, A., Hruby, G., Eade, T., Nguyen, Q., Thompson, B., Cusick, T., et al (2018). The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. Journal of Nuclear Medicine, 59(1), 82-88. [More Information]
• Kroon, H., van der Bol, W., Tonks, K., Hong, A., Hruby, G., Thompson, J. (2018). Treatment of Clinically Positive Cervical Lymph Nodes by Limited Local Node Excision and Adjuvant Radiotherapy in Melanoma Patients with Major Comorbidities. Annals of Surgical Oncology, 25(12), 3476-3482. [More Information]

2017

• Choong, E., Hruby, G., Yang, J., Kwong, C., Patanjali, N. (2017). 78Gy with Fiducial Marker Image-Guided Radiotherapy in Prostate Cancer: Single Center Analysis of 301 Patients. Asia-Pacific Journal of Clinical Oncology, 13(5), e356-e363. [More Information]
• Hruby, G., Eade, T., Kneebone, A., Emett, L., Guo, L., Ho, B., Hsiao, E., Schembri, G., Hunter, J., Kwong, C. (2017). Delineating biochemical failure with (68)Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. Radiotherapy and Oncology, 122(1), 99-102. [More Information]
• Bell, L., Eade, T., Kneebone, A., Hruby, G., Alfieri, F., Bromley, R., Grimberg, K., Barnes, M., Booth, J. (2017). Initial experience with intra-fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment. Journal of Medical Radiation Sciences, 64(1), 25-34. [More Information]
• Byrne, K., Hruby, G., Kneebone, A., Whalley, D., Guo, L., McCloud, P., Eade, T. (2017). Late Genitourinary Toxicity Outcomes in 300 Prostate Cancer Patients Treated With Dose-escalated Image-guided Intensity-modulated Radiotherapy. Clinical Oncology, 29(9), 617-625. [More Information]
• Itchins, M., Arena, J., Nahm, C., Rabindran, J., Kim, S., Gibbs, E., Bergamin, S., Chua, T., Gill, A., Maher, R., Diakos, C., Mittal, A., Hruby, G., Kneebone, A., Pavlakis, N., Samra, J., Clarke, S., et al (2017). Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre. European Journal of Surgical Oncology, 43(9), 1711-1717. [More Information]
• Emmett, L., van Leeuwen, P., Nandurkar, R., Scheltema, M., Cusick, T., Hruby, G., Kneebone, A., Eade, T., Fogarty, G., et al (2017). TREATMENT OUTCOMES FROM 68GAPSMA PET CT INFORMED SALVAGE RADIATION TREATMENT IN MEN WITH RISING PSA FOLLOWING RADICAL PROSTATECTOMY: PROGNOSTIC VALUE OF A NEGATIVE PSMA PET. The Journal of Nuclear Medicine, 58, 1972-1976. [More Information]

2016

• van Leeuwen, P., Stricker, P., Hruby, G., Kneebone, A., Ting, F., Thompson, B., Nguyen, Q., Ho, B., Emmett, L. (2016). 68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU International, 117(5), 732-739. [More Information]
• Oh, B., Figtree, G., Costa, D., Eade, T., Hruby, G., Lim, S., Elfiky, A., Martine, N., Rosenthal, D., Clarke, S., Back, M. (2016). Oxidative stress in prostate cancer patients: A systematic review of case control studies. Prostate International, 4(3), 71-87. [More Information]
• Whalley, D., Hruby, G., Alfieri, F., Kneebone, A., Eade, T. (2016). SpaceOAR Hydrogel in Dose-escalated Prostate Cancer Radiotherapy: Rectal Dosimetry and Late Toxicity. Clinical Oncology, 28(10), e148-e154. [More Information]
• Smith, B., Butow, P., Olver, I., Luckett, T., Grimison, P., Toner, G., Stockler, M., Hovey, E., Stubbs, J., Turner, S., Gurney, H., King, M., et al (2016). The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. Journal of Cancer Survivorship, 10(2), 223-233. [More Information]

2015

• Butow, P., Kelly, S., Thewes, B., Hruby, G., Sharpe, L., Beith, J. (2015). Attentional bias and metacognitions in cancer survivors with high fear of cancer recurrence. Psycho-Oncology, 24(4), 416-423. [More Information]
• Honeyball, F., Murali-Ganesh, R., Hruby, G., Grimison, P. (2015). Compliance of males with stage 1 testicular germ cell tumours on an active surveillance protocol. Internal Medicine Journal, 45(10), 1081-1084. [More Information]
• Fogarty, G., Hong, A., Dolven-Jacobson, K., Reisse, C., Burmeister, B., Haydu, L., Dhillon, H., Steel, V., Shivalingam, B., Drummond, K., Vardy, J., Hruby, G., Scolyer, R., Thompson, J., et al (2015). First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Research Notes, 8, 1-6. [More Information]
• Bece, A., Patanjali, N., Jackson, M., Whitaker, M., Hruby, G. (2015). High-dose-rate brachytherapy boost for prostate cancer: Outcomes and genitourinary toxicity. Brachytherapy, 14(5), 670-676. [More Information]
• Yates, A., Carroll, S., Kneebone, A., Tse, R., Horvath, L., Byrne, C., Solomon, M., Hruby, G. (2015). Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions. Clinical Oncology, 27(12), 700-707. [More Information]
• Morigi, J., Stricker, P., van Leeuwen, P., Tang, R., Ho, B., Nguyen, Q., Hruby, G., Fogarty, G., Jagavkar, R., Kneebone, A., et al (2015). Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. The Journal of Nuclear Medicine, 56(8), 1185-1190. [More Information]
• Jones, M., Hruby, G., Solomon, M., Rutherford, N., Martin, J. (2015). The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 22(11), 3574-3581. [More Information]
• Wong, S., Waldeck, K., Vergara, I., Schroder, J., Madore, J., Wilmott, J., Colebatch, A., De Paoli-Iseppi, R., Li, J., Lupat, R., Hruby, G., Mann, G., Thompson, J., Scolyer, R., Gill, A., et al (2015). UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 75(24), 5228-5234. [More Information]

2014

• Suttie, C., Hruby, G., Horvath, L., Thompson, J. (2014). Cardiac metastasis in Merkel cell carcinoma. Journal of Clinical Oncology, 32(13), e52-e53. [More Information]
• Thompson, S., Delaney, G., Gabriel, G., Izard, M., Hruby, G., Jagavkar, R., Bucci, J., Barton, M. (2014). Prostate brachytherapy in New South Wales: Patterns of care study and impact of caseload on treatment quality. Journal of Contemporary Brachytherapy, 6(4), 344-349. [More Information]
• Elsner, K., Francis, K., Hruby, G., Roderick, S. (2014). Quality improvement process to assess tattoo alignment, set-up accuracy and isocentre reproducibility in pelvic radiotherapy patients. Journal of Medical Radiation Sciences, 61, 246-252. [More Information]
• Naehrig, D., Uren, R., Emmett, L., Ioannou, K., Hong, A., Wratten, C., Thompson, J., Hruby, G. (2014). Sentinel lymph node mapping for defining site and extent of elective radiotherapy management of regional nodes in Merkel cell carcinoma: a pilot case series. Journal of Medical Imaging and Radiation Oncology, 58(3), 353-359. [More Information]
• Foroudi, F., Pham, D., Rolfo, A., Bressel, M., Tang, C., Tan, A., Turner, S., Hruby, G., Williams, S., Hayne, D., et al (2014). The outcome of a multi-centre feasibility study of online adaptive radiotherapy for muscle-invasive bladder cancer TROG 10.01 BOLART. Radiotherapy and Oncology, 111(2), 316-320. [More Information]
• Thompson, J., Hruby, G. (2014). The role of sentinel lymph node biopsy in patients with merkel cell carcinoma: uncertainty prevails. Annals of Surgical Oncology, 21(5), 1517-1519. [More Information]

2013

• Gzell, C., Kench, J., Stockler, M., Hruby, G. (2013). Biopsy-proven brain metastases from prostate cancer: a series of four cases with review of the literature. International Urology and Nephrology, 45(3), 735-742. [More Information]
• Finnigan, R., Hruby, G., Wratten, C., Keller, J., Tripcony, L., Dickie, G., Rischin, D., Poulsen, M. (2013). The Impact of Preradiation Residual Disease Volume on Time to Locoregional Failure in Cutaneous Merkel Cell Carcinoma-A TROG Substudy. International Journal of Radiation Oncology Biology Physics, 86(1), 91-95. [More Information]
• Hruby, G., Scolyer, R., Thompson, J. (2013). The important role of radiation treatment in the management of Merkel cell carcinoma. British Journal of Dermatology, 169(5), 975-982. [More Information]
• Smith, B., King, M., Butow, P., Luckett, T., Grimison, P., Toner, G., Stockler, M., Hovey, E., Stubbs, J., Hruby, G., Gurney, H., Turner, S., et al (2013). The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. Psycho-Oncology, 22(11), 2557-2564. [More Information]
• Hillen, M., Butow, P., Tattersall, M., Hruby, G., Boyle, F., Vardy, J., Kallimanis-King, B., de Haes, H., Smets, E. (2013). Validation of the English version of the Trust in Oncologist Scale (TiOS). Patient Education and Counseling, 91(1), 25-28. [More Information]

2012

• Martin, D., Hruby, G., Whitaker, M., Foo, K. (2012). Constrained-beam inverse planning for intensity-modulated radiation therapy of prostate cancer patients with bilateral hip prostheses. Journal of Medical Imaging and Radiation Oncology, 56(6), 703-707. [More Information]
• Sundaresan, P., Hruby, G., Hamilton, A., Hong, A., Boyer, M., Chatfield, M., Thompson, J. (2012). Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma. Clinical Oncology, 24(9), e131-e136. [More Information]
• Whalley, D., Patanjali, N., Jackson, M., Lovett, A., Chatfield, M., Hruby, G. (2012). HDR brachytherapy combined with external beam radiation for localised prostate cancer: Early experience from the Sydney Cancer Centre. Journal of Medical Imaging and Radiation Oncology, 56(2), 220-226. [More Information]
• Dear, R., Barratt, A., Evans, A., Simes, R., Newsom, J., Kent, D., Crossing, S., Holliday, C., Segelov, E., Hruby, G., Tattersall, M. (2012). Identifying and prioritising gaps in colorectal cancer trials research in Australia. Medical Journal of Australia, 197(9), 507-511. [More Information]
• Lim, C., Whalley, D., Haydu, L., Murali, R., Tippett, J., Thompson, J., Hruby, G., Scolyer, R. (2012). Increasing Tumor Thickness is Associated with Recurrence and Poorer Survival in Patients with Merkel Cell Carcinoma. Annals of Surgical Oncology, 19(11), 3325-3334. [More Information]
• Goldstein, D., Spry, N., Cummins, M., Brown, C., van Hazel, G., Carroll, S., Selva-Nayagam, S., Borg, M., Ackland, S., Wratten, C., Hruby, G., Horvath, L., Gebski, V., et al (2012). The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer, 106(1), 61-69. [More Information]
• Gee, H., Hruby, G. (2012). Update on the Management of Merkel Cell Carcinoma. Cancer Forum, 36(3), 1-5. [More Information]

2011

• Suchowerska, N., Jackson, M., Lambert, J., Yin, Y., Hruby, G., McKenzie, D. (2011). Clinical Trials of a Urethral Dose Measurement System in Brachytherapy Using Scintillation Detectors. International Journal of Radiation: Oncology - Biology - Physics, 79(2), 609-615. [More Information]
• Chen, J., Hruby, G., Stockler, M., Patanjali, N., Bucci, J., Perez, G., Loadsman, J., Sheehan, E. (2011). Patient-reported outcomes of prostate high-dose-rate brachytherapy boost comparing an outpatient and inpatient protocol: A two-center chronologic cohort study. Brachytherapy, 10(6), 454-460. [More Information]
• Hruby, G., Chen, J., Bucci, J., Loadsman, J., Perry, P., Stockler, M. (2011). Patients' experiences of high-dose-rate brachytherapy boost for prostate cancer using an inpatient protocol. Brachytherapy, 10(5), 395-400. [More Information]
• Whitaker, M., Hruby, G., Lovett, A., Patanjali, N. (2011). Prostate HDR brachytherapy catheter displacement between planning and treatment delivery. Radiotherapy and Oncology, 101(3), 490-494. [More Information]
• Fogarty, G., Morton, R., Vardy, J., Nowak, A., Mandel, C., Forder, P., Hong, A., Hruby, G., Burmeister, B., Shivalingam, B., Dhillon, H., Thompson, J. (2011). Whole brain radiotherapy after local treatment of brain metastases in melanoma patients - a randomised phase III trial. BMC Cancer, 11(142), 1-8. [More Information]

2009

• Zajac, J., Solomon, M., Hruby, G., Frizelle, F. (2009). Review of 120 anal cancer patients. Colorectal Disease, 11, 909-14. [More Information]

2008

• Doyle, C., Loadsman, J., Hruby, G. (2008). An audit of analgesia requirements for high-dose-rate prostate brachytherapy. Anaesthesia and Intensive Care, 36(5), 707-709. [More Information]
• Broadbent, A., Hruby, G. (2008). Brain secondaries. In N. Christakis and P. Glare (Eds.), Prognosis in Advanced Cancer, (pp. 285-294). Oxford: Oxford University Press.
• Chen, J., Hruby, G., Scolyer, R., Murali, R., Hong, A., FitzGerald, P., Pham, T., Quinn, M., Thompson, J. (2008). Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer, 113(10), 2770-2778. [More Information]
• Warner, R., Quinn, M., Hruby, G., Scolyer, R., Uren, R., Thompson, J. (2008). Management of Merkel Cell Carcinoma: The Roles of Lymphoscintigraphy, Sentinel Lymph Node Biopsy and Adjuvant Radiotherapy. Annals of Surgical Oncology, 15(9), 2509-2518. [More Information]
• Harrison, J., Solomon, M., Young, J., Meagher, A., Butow, P., Salkeld, G., Hruby, G., Clarke, S. (2008). Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. JAMA (formerly Archives Of Surgery), 143(4), 389-394. [More Information]

2007

• Jabbour, J., Cumming, R., Scolyer, R., Hruby, G., Thompson, J., Lee, S. (2007). Merkel Cell Carcinoma: Assessing the Effect of Wide Local Excision, Lymph Node Dissection, and Radiotherapy on Recurrence and Survival in Early-Stage Disease-Results From a Review of 82 Consecutive Cases Diagnosed Between 1992 and 2004. Annals of Surgical Oncology, 14(6), 1943-1952. [More Information]
• Harrison, J., Solomon, M., Young, J., Meagher, A., Hruby, G., Salkeld, G., Clarke, S. (2007). Surgical and oncology trials for rectal cancer: Who will participate? Surgery, 142(1), 94-101. [More Information]

2006

• Butow, P., Solomon, M., Young, J., Whelan, T., Salkeld, G., Wilson, K., Harrison, J., Hruby, G., Mansour, O., Kennedy, N., Tattersall, M. (2006). Consumer impact of an interactive decision aid for rectal cancer patients offered adjuvant therapy. Colorectal Disease, 8(8), 676-682. [More Information]

2004

• Broadbent, A., Hruby, G., Tin, M., Jackson, M., Firth, I. (2004). Survival Following Whole Brain Radiation Treatment For Cerebral Metastases: An Audit Of 474 Patients. Radiotherapy and Oncology, 71(3), 259-265. [More Information]

2002

• Hruby, G., Choo, R., Jackson, M., Warde, P., Sandler, H. (2002). Management preferences following radical inguinal orchidectomy for Stage 1 testicular seminoma in Australasia. Journal of Medical Imaging and Radiation Oncology, 46(3), 280-284. [More Information]